Alnylam Pharmaceuticals Inc (DUL F) stock market data APIs
€392.8782
-8.73(-2.2%)
as of October 31, 2025
Try our APIs with
free plan!
Alnylam Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Prev. Close
392.8782
Open
384.1451
High
400.6053
Low
387.5048
52 wk Range
198.7-423
Market Cap
52 067 M
P/E Ratio
1454.0741
Shares Outstanding
132 M
Revenue
3 210 M
Beta
0.353
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alnylam Pharmaceuticals Inc data using free add-ons & libraries
Get Alnylam Pharmaceuticals Inc Fundamental Data
Alnylam Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 3 210 M
- EBITDA: 321 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 1.75
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alnylam Pharmaceuticals Inc News
New
Alnylam Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) defied analyst predictions to release its third-quarter results, which were ahead of market expectations. Statutory earnings performance was extremely stron...
How Alnylam's Raised 2025 Revenue Outlook and AMVUTTRA Uptake Will Impact ALNY Investors
Alnylam Pharmaceuticals reported third-quarter 2025 earnings, achieving US$1.25 billion in revenue and a net income of US$251.08 million, while also raising full-year revenue guidance to between US$2....
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Alnylam Pharmaceuticals ALNY reported third-quarter 2025 earnings of $2.90 per share, beating the Zacks Consensus Estimate of $1.67. The improvement was due to higher revenues from the sale of its lea...
Alnylam Pharmaceuticals Inc (ALNY) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ...
This article first appeared on GuruFocus. Total Product Revenues: $851 million, 103% growth year-over-year. TTR Franchise Revenue: $724 million, 135% year-over-year growth. US TTR Revenue: $543 milli...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
